Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study
- PMID: 12853793
- DOI: 10.1097/01.ju.0000070437.14275.e0
Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study
Abstract
Purpose: We determined the long-term outcome in patients with superficial bladder cancer (Ta and T1) undergoing routine second transurethral bladder tumor resection (ReTURB) in regard to recurrence and progression.
Materials and methods: We performed an inception cohort study of 124 consecutive patients with superficial bladder cancer undergoing transurethral resection and routine ReTURB (83) between November 1993 and October 1995 at a German university hospital. Immediately after transurethral resection all lesions were documented on a designed bladder map. ReTURB of the scar from initial resection and other suspicious lesions was performed at a mean of 7 weeks. Patients were followed until recurrence or death, or a minimum of 5 years.
Results: Residual tumor was found in 33% of all ReTURB cases, including 27% of Ta and 53% of T1 disease, and in 81% at the initial resection site. Five of the 83 patients underwent radical cystectomy due to ReTURB findings. The estimated risk of recurrence after years 1 to 3 was 18%, 29% and 32%, respectively. After 5 years 63% of the patients undergoing ReTURB were still disease-free (mean recurrence-free survival 62 months, median 87). Progression to muscle invasive disease was observed in only 2 patients (3%) after a mean observation of 61 months.
Conclusions: These data suggest a favorable outcome regarding recurrence and progression in patients with superficial bladder cancer who undergo ReTURB. ReTURB is suggested at least in those at high risk when bladder preservation is intended.
Similar articles
-
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x. BJU Int. 2004. PMID: 15610101
-
Prognostic impact of ReTURB in high grade T1 primary bladder cancer.Arch Ital Urol Androl. 2016 Jul 4;88(2):81-5. doi: 10.4081/aiua.2016.2.81. Arch Ital Urol Androl. 2016. PMID: 27377079
-
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272. Arch Ital Urol Androl. 2017. PMID: 29473376
-
Management of high-risk non-muscle invasive bladder cancer.Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Minerva Urol Nefrol. 2012. PMID: 23288212 Review.
-
The role of repeat transurethral resection in the management of high-risk superficial transitional cell bladder cancer.BJU Int. 2005 Oct;96(6):759-62. doi: 10.1111/j.1464-410X.2005.05710.x. BJU Int. 2005. PMID: 16153194 Review. No abstract available.
Cited by
-
Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE).Bladder Cancer. 2016 Jan 7;2(1):27-36. doi: 10.3233/BLC-150034. Bladder Cancer. 2016. PMID: 27376122 Free PMC article. Review.
-
Bladder cancer: Restaging TUR reduces recurrence and progression risk.Nat Rev Urol. 2010 Dec;7(12):649-50. doi: 10.1038/nrurol.2010.189. Nat Rev Urol. 2010. PMID: 21139639
-
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.J Urol. 2014 Feb;191(2):341-5. doi: 10.1016/j.juro.2013.08.022. Epub 2013 Aug 20. J Urol. 2014. PMID: 23973518 Free PMC article.
-
NBI - plasma vaporization hybrid approach in bladder cancer endoscopic management.J Med Life. 2014 Jun 15;7(2):155-9. Epub 2014 Jun 25. J Med Life. 2014. PMID: 25408719 Free PMC article. Clinical Trial.
-
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8. Can Urol Assoc J. 2016. PMID: 26977213 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical